Safety: what we know, what we dont What clinical trial safety reviews suggest The clinical safety review literature reports several reassuring signals: No meaningful increase in IGF-1 in monitored long-term studies (jofem.org) No clear negative effect on carbohydrate metabolism in testing described (contrast with full hGH) (jofem.org) No clear immunogenicity signal (e.g., anti-AOD antibodies) in the subset assessed in those trials (jofem.org) The major limitation: long-term real-world certainty is thin The problem with many peptides is not that everything is dangerousits that the certainty level is often lower than patients assume
Continue daily injections until symptoms stop improving, because some of them may not be fully reversible
If you inject AOD-9604 while insulin is elevated, you're essentially throwing it into an environment that's fighting its mechanism
[DOI] [PMC free article] [PubMed] 38.Bonomini M., Pandolfi A., Di Liberato L., Di Silvestre S., Cnops Y., Di Tomo P., D'Arezzo M., Monaco M.P., Giardinelli A., Di Pietro N., et al
